Brugia pahangi and Wolbachia: the kinetics of bacteria elimination, worm viability, and host responses following tetracycline treatment.
Wolbachia spp., first reported from filariae nearly 30 years ago, have been suggested to contribute to the pathogenesis associated with human filarial infection. Tetracycline has been used to cure filariae of Wolbachia, as a novel means of chemotherapeutic treatment for both ocular and lymphatic filariasis. Tetracycline treatment of L4 or adult Brugia pahangi in vivo resulted in Wolbachia clearance. Less tetracycline was required to clear Wolbachia when treatment began at the L4 stage, compared with adults. Female worms died earlier than male worms when tetracycline was administered at the L4 stage. In all cases, Wolbachia clearance was closely associated with worm death. Worm recoveries decreased following the L4-L5 molt, suggesting tetracycline does not interrupt molting in this model system. Despite worm death and the assumed release of both bacterial- and worm-derived molecules, differences in inflammatory cell population and T cell cytokine mRNA profiles were negligible between tetracycline-treated and non-treated B. pahangi infected gerbils. These data suggest the contribution of Wolbachia to the in vivo induction of the gerbil immune response to B. pahangi may be small.
Chirgwin
Sharon R
SR
Department of Pathobiological Science, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803, USA.
Nowling
Jena M
JM
Coleman
Sharon U
SU
Klei
Thomas R
TR
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D015139:Blotting, Southern; D017179:Brugia pahangi / Q000187:drug effects / Q000382:microbiology* / Q000502:physiology; D002452:Cell Count; D016207:Cytokines / Q000032:analysis; D004269:DNA, Bacterial / Q000032:analysis; D005260:Female; D005298:Fertility; D005368:Filariasis / Q000188:drug therapy* / Q000276:immunology / Q000469:parasitology; D005849:Gerbillinae; D008297:Male; D010529:Peritoneal Cavity / Q000473:pathology; D016133:Polymerase Chain Reaction; D011897:Random Allocation; D013752:Tetracycline / Q000494:pharmacology* / Q000627:therapeutic use; D020577:Wolbachia / Q000187:drug effects* / Q000302:isolation & purification / Q000502:physiology
D000900:Anti-Bacterial Agents; D016207:Cytokines; D004269:DNA, Bacterial; D013752:Tetracycline